An advanced well-differentiated pancreatic neuroendocrine carcinoma (NET-G3) associated with von hippel-lindau disease

Masami Miki; Ken Kawabe; Hisato Igarashi; Tatsuro Abe; Yoshihiro Ohishi; Risa Hashimoto; Takashi Karashima; Ichiro Yamasaki; Keiji Inoue; Tetsuhide Ito; Yoshihiro Ogawa

doi:10.2169/internalmedicine.0416-17

An advanced well-differentiated pancreatic neuroendocrine carcinoma (NET-G3) associated with von hippel-lindau disease

Masami Miki, Ken Kawabe, Hisato Igarashi, Tatsuro Abe, Yoshihiro Ohishi, Risa Hashimoto, Takashi Karashima, Ichiro Yamasaki, Keiji Inoue, Tetsuhide Ito, Yoshihiro Ogawa

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

A 45-year old woman who underwent several surgeries for tumors associated with von Hippel-Lindau disease (VHL) was referred to our hospital due to a pancreatic tumor and liver tumors. She was diagnosed with pancreatic neuroendocrine tumor (NET) with a Ki67 index of 40% based on the examination of a biopsy specimen of the liver tumors. She was treated with everolimus for 6 months and sunitinib for 6 weeks as first-and second-line therapies. She survived for 13 months. At autopsy the diagnosis of pancreatic neuroendocrine tumor (NET)-G3 was confirmed. We herein report an aggressive clinical course of VHL-related NET G3. The further accumulation of cases is required to reach a consensus on treatment for this disease.

Original language	English
Pages (from-to)	2007-2011
Number of pages	5
Journal	Internal Medicine
Volume	57
Issue number	14
DOIs	https://doi.org/10.2169/internalmedicine.0416-17
Publication status	Published - 2018

All Science Journal Classification (ASJC) codes

Internal Medicine

Access to Document

10.2169/internalmedicine.0416-17

Cite this

@article{d23fa36bd2404212a2e81feb4b879a70,

title = "An advanced well-differentiated pancreatic neuroendocrine carcinoma (NET-G3) associated with von hippel-lindau disease",

abstract = "A 45-year old woman who underwent several surgeries for tumors associated with von Hippel-Lindau disease (VHL) was referred to our hospital due to a pancreatic tumor and liver tumors. She was diagnosed with pancreatic neuroendocrine tumor (NET) with a Ki67 index of 40% based on the examination of a biopsy specimen of the liver tumors. She was treated with everolimus for 6 months and sunitinib for 6 weeks as first-and second-line therapies. She survived for 13 months. At autopsy the diagnosis of pancreatic neuroendocrine tumor (NET)-G3 was confirmed. We herein report an aggressive clinical course of VHL-related NET G3. The further accumulation of cases is required to reach a consensus on treatment for this disease.",

author = "Masami Miki and Ken Kawabe and Hisato Igarashi and Tatsuro Abe and Yoshihiro Ohishi and Risa Hashimoto and Takashi Karashima and Ichiro Yamasaki and Keiji Inoue and Tetsuhide Ito and Yoshihiro Ogawa",

note = "Publisher Copyright: {\textcopyright} 2018 The Japanese Society of Internal Medicine.",

year = "2018",

doi = "10.2169/internalmedicine.0416-17",

language = "English",

volume = "57",

pages = "2007--2011",

journal = "Internal Medicine",

issn = "0918-2918",

publisher = "Japanese Society of Internal Medicine",

number = "14",

}

TY - JOUR

T1 - An advanced well-differentiated pancreatic neuroendocrine carcinoma (NET-G3) associated with von hippel-lindau disease

AU - Miki, Masami

AU - Kawabe, Ken

AU - Igarashi, Hisato

AU - Abe, Tatsuro

AU - Ohishi, Yoshihiro

AU - Hashimoto, Risa

AU - Karashima, Takashi

AU - Yamasaki, Ichiro

AU - Inoue, Keiji

AU - Ito, Tetsuhide

AU - Ogawa, Yoshihiro

PY - 2018

Y1 - 2018

N2 - A 45-year old woman who underwent several surgeries for tumors associated with von Hippel-Lindau disease (VHL) was referred to our hospital due to a pancreatic tumor and liver tumors. She was diagnosed with pancreatic neuroendocrine tumor (NET) with a Ki67 index of 40% based on the examination of a biopsy specimen of the liver tumors. She was treated with everolimus for 6 months and sunitinib for 6 weeks as first-and second-line therapies. She survived for 13 months. At autopsy the diagnosis of pancreatic neuroendocrine tumor (NET)-G3 was confirmed. We herein report an aggressive clinical course of VHL-related NET G3. The further accumulation of cases is required to reach a consensus on treatment for this disease.

AB - A 45-year old woman who underwent several surgeries for tumors associated with von Hippel-Lindau disease (VHL) was referred to our hospital due to a pancreatic tumor and liver tumors. She was diagnosed with pancreatic neuroendocrine tumor (NET) with a Ki67 index of 40% based on the examination of a biopsy specimen of the liver tumors. She was treated with everolimus for 6 months and sunitinib for 6 weeks as first-and second-line therapies. She survived for 13 months. At autopsy the diagnosis of pancreatic neuroendocrine tumor (NET)-G3 was confirmed. We herein report an aggressive clinical course of VHL-related NET G3. The further accumulation of cases is required to reach a consensus on treatment for this disease.

UR - http://www.scopus.com/inward/record.url?scp=85050090288&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050090288&partnerID=8YFLogxK

U2 - 10.2169/internalmedicine.0416-17

DO - 10.2169/internalmedicine.0416-17

M3 - Article

C2 - 29491307

AN - SCOPUS:85050090288

SN - 0918-2918

VL - 57

SP - 2007

EP - 2011

JO - Internal Medicine

JF - Internal Medicine

IS - 14

ER -

An advanced well-differentiated pancreatic neuroendocrine carcinoma (NET-G3) associated with von hippel-lindau disease

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this